Literature DB >> 7478539

UREB1, a tyrosine phosphorylated nuclear protein, inhibits p53 transactivation.

J Gu1, R Dubner, A J Fornace, M J Iadarola.   

Abstract

Tumor suppressor p53 is a transcription activator that upregulates target genes containing the p53 binding site. UREB1, a DNA binding protein that is tyrosine phosphorylated in vivo, shares a significant homology with the human papilloma virus E6 associated protein (E6-AP). E6-AP forms a ternary complex with E6 and p53 and participates in the ubiquitination of p53. Based on the homology with E6-AP, but taking into account the nuclear localization of UREB1 and its smaller size, the present study used a transient transfection system to examine whether UREB1 influenced p53-stimulated transcription. Co-transfection of a vector expressing wildtype UREB1 with one expressing p53 into H1299, a p53 negative cell line, resulted in a pronounced suppression of p53 transactivation. The inhibitory effect was significantly attenuated by mutation of a tyrosine residue in the consensus tyrosine phosphorylation sequence of UREB1. These data suggest that optimal suppression of p53 transactivation requires tyrosine phosphorylated UREB1 and that tyrosine phosphorylation and dephosphorylation processes may be involved in the regulation of p53 transactivation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7478539

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Characterization of E3Histone, a novel testis ubiquitin protein ligase which ubiquitinates histones.

Authors:  Zhiqian Liu; Rose Oughtred; Simon S Wing
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

2.  The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily.

Authors:  Z Nawaz; D M Lonard; C L Smith; E Lev-Lehman; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

Review 3.  ARF-BP1 as a potential therapeutic target.

Authors:  D Chen; C L Brooks; W Gu
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

4.  HUWE1 controls the development of non-small cell lung cancer through down-regulation of p53.

Authors:  Dong Yang; Daomei Cheng; Qiu Tu; Huihui Yang; Bin Sun; Lanzhen Yan; Hongjuan Dai; Jierong Luo; Bingyu Mao; Yi Cao; Xiaoping Yu; Hua Jiang; Xudong Zhao
Journal:  Theranostics       Date:  2018-06-06       Impact factor: 11.556

Review 5.  HECT E3s and human disease.

Authors:  Martin Scheffner; Olivier Staub
Journal:  BMC Biochem       Date:  2007-11-22       Impact factor: 4.059

6.  HUWE1 mutations in Juberg-Marsidi and Brooks syndromes: the results of an X-chromosome exome sequencing study.

Authors:  Michael J Friez; Susan Sklower Brooks; Roger E Stevenson; Michael Field; Monica J Basehore; Lesley C Adès; Courtney Sebold; Stephen McGee; Samantha Saxon; Cindy Skinner; Maria E Craig; Lucy Murray; Richard J Simensen; Ying Yzu Yap; Marie A Shaw; Alison Gardner; Mark Corbett; Raman Kumar; Matthias Bosshard; Barbara van Loon; Patrick S Tarpey; Fatima Abidi; Jozef Gecz; Charles E Schwartz
Journal:  BMJ Open       Date:  2016-04-29       Impact factor: 2.692

7.  Syk-mediated tyrosine phosphorylation of mule promotes TNF-induced JNK activation and cell death.

Authors:  C K Lee; Y Yang; C Chen; J Liu
Journal:  Oncogene       Date:  2015-07-27       Impact factor: 9.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.